Shots:
- Merck & Daiichi Sankyo have dosed first pts with ifinatamab deruxtecan (I-DXd) in its P-III (IDeate-Prostate01) trial for metastatic castration-resistant prostate cancer (mCRPC), which was initiated based on positive P-I/II (IDeate-PanTumor01) trial data
- The P-III (IDeate-Prostate01) trial will evaluate I-DXd (12mg/kg) vs docetaxel (75mg/m²) plus corticosteroid in ~1440 mCRPC pts, who progressed during or after ≥8wks. of 1 or 2 androgen receptor pathway inhibitor therapy
- Trial will assess OS & rPFS as dual 1EPs, with 2EPs, incl. ORR, time to first subsequent therapy, DoR, time to pain progression, time to PSA progression, PSA response, time to first symptomatic skeletal-related event & safety
Ref: Merck | Image: Merck and Daiichi | Press Release
Related News:- Brain Navi Biotechnology Reports the US FDA’s 510(k) Clearance of NaoTrac for Neurosurgical Procedures
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
